DEF: CareDx Sets June 11 Annual Meeting, Proposes Equity Plan Boost

CareDx, Inc. announced its 2026 Annual Meeting of Stockholders, scheduled for June 11, 2026, to elect directors, ratify auditor appointment, and approve an amendment to increase shares available under its 2024 Equity Incentive Plan.

Summary

• CareDx, Inc. has announced its 2026 Annual Meeting of Stockholders, to be held virtually on June 11, 2026.
• The meeting agenda includes the election of five directors, ratification of Deloitte & Touche LLP as the independent auditor for fiscal year 2026, an advisory vote on executive compensation, an advisory vote on the frequency of executive compensation votes, and approval of an amendment to the 2024 Equity Incentive Plan.
• The proposed amendment to the 2024 Equity Incentive Plan seeks to increase the available shares by 1,600,000, representing approximately 3.1% of currently outstanding common shares.
• The company aims to align equity compensation with attracting and retaining talent, linking executive and employee interests with stockholder interests.
• As of March 31, 2026, CareDx had 1,855,798 shares available for grant under its equity plans, with the 2024 Plan having 1,786,835 shares available.
• The company projects its Gross Burn Rate for 2026 to be approximately 3-4% and its Net Burn Rate to be approximately 2-3%, which are anticipated to be below industry benchmarks.
• The filing details the compensation of Named Executive Officers (NEOs) for fiscal year 2025, including base salaries, annual incentives, and long-term equity awards.
• John W. Hanna, President and CEO, reported total compensation of $7,179,699 in 2025.
• The company is also providing information on director compensation, corporate governance practices, and security ownership by major stockholders and management.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, reflecting standard corporate governance procedures and a forward-looking approach to talent management, balanced by the company's reported net loss.

Positives

• The company is proactively seeking to align executive and employee interests with stockholders through equity incentives.
• CareDx is focused on reducing its burn rate and dilution, with projected 2026 Net Burn Rate of 2-3%, below industry benchmarks.
• The company has strong governance practices in place, including an independent board chairman, stock ownership guidelines for executives and directors, and a clawback policy.
• The proposed increase in the equity incentive plan shares is intended to support talent acquisition and retention, crucial for growth.
• The company's 2025 revenue grew by 14% year-over-year, with testing services revenue up 10% and patient and digital solutions revenue up 31%.

Negatives

• The company reported a net loss of $21 million for fiscal year 2025.
• As of December 31, 2025, the company had $200 million in cash, cash equivalents, and marketable securities, but the net loss indicates ongoing operational costs.
• A significant portion of outstanding stock options are 'underwater' (exercise price above current market price), with 1,282,713 options at an average strike price of $30 being underwater as of March 31, 2026.

Risks

• The company operates in a highly competitive labor market, requiring strong management and competitive compensation to attract and retain talent.
• Competitors may have substantially greater capital resources and larger sales forces.
• The diagnostics industry is characterized by rapid product development and technological advances, requiring management to be adept at managing these areas.
• The proposed increase in the equity incentive plan shares could lead to increased dilution if not managed effectively.
• The company's forward-looking statements are subject to various risks, uncertainties, and assumptions, and actual results could differ materially.

Future Outlook

The company is focused on executing its strategy to advance long-term value creation, building a durable financial profile, and enabling life-changing solutions for transplant patients. The proposed increase in the equity incentive plan shares is intended to support talent acquisition and retention, aligning with the company's growth objectives. The company anticipates its 2026 Gross Burn Rate to be approximately 3-4% and Net Burn Rate to be approximately 2-3%, aiming to remain below industry benchmarks.

Management Comments

• "2025 was a year of strong execution for CareDx, as we advanced the longterm strategy we outlined at our Investor Day in October 2024."
• "Over the past year, we sharpened our focus, strengthened our operating foundation, and made deliberate investments to support sustainable growth and longterm value creation."
• "I am proud of what our team accomplished in 2025 and grateful for the continued confidence of our stockholders."
• "We remain focused on executing our strategy and advancing our vision of a world where every patient receives the care they need to live longer, fuller lives."

Industry Context

StockSavvy.ai notes that CareDx operates in the precision medicine and diagnostics sector, a field characterized by rapid technological advancements and a competitive landscape. The company's focus on transplant patient care and genomics-based information positions it within a specialized niche. The proposed equity incentive plan increase reflects the industry's reliance on equity compensation for talent acquisition and retention in a competitive market.

Comparison to Industry Standards

• CareDx's projected 2026 Gross Burn Rate of 3-4% and Net Burn Rate of 2-3% are anticipated to be below the ISS industry benchmark for Pharmaceuticals, Biotechnology & Life Sciences, which is 6.23% for 2026.
• The company's 2025 gross burn rate was below the ISS industry benchmark for 2025.
• The company's peer group for compensation decisions includes companies like 10x Genomics, Adaptive Biotechnologies, Guardant Health, Natera, and Veracyte, which are all significant players in the life sciences and diagnostics sectors.

Corporate Governance

Stakeholder Impact

• Shareholders will vote on key corporate matters, including director elections and equity plan amendments, directly impacting their ownership and potential dilution.
• Employees and executives will be affected by the proposed increase in equity awards, which is intended to incentivize performance and retention.
• The company's financial performance and strategic decisions, as outlined in the filing, will influence investor confidence and the company's long-term viability.

Next Steps

• Stockholders are encouraged to vote on the proposals presented at the 2026 Annual Meeting of Stockholders.
• The company will file a Form 8-K with preliminary voting results within four business days after the Annual Meeting.
• Stockholder proposals for the 2027 annual meeting must be received by December 30, 2026, for inclusion in the proxy statement.

Key Dates

Recommendation

The filing is a routine proxy statement for an annual meeting. While it outlines proposals for director elections and an equity plan increase aimed at talent retention, it also highlights a net loss for the fiscal year. The company's financial performance and the potential for dilution from the equity plan increase warrant a cautious 'hold' stance until further clarity on future performance and strategic execution is provided.

Keywords

CareDx, Proxy Statement, Annual Meeting, Equity Incentive Plan, Director Election, Executive Compensation, Auditor Ratification, Stockholder Vote, Burn Rate, Dilution, CDNA